ClinicalTrials.gg
Active, not recruitingNCT05561309Updated Mar 4, 2024

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management

A Phase 2 interventional study of HR18034;Ropivacaine Hydrochloride Injection in Total Knee Arthroplasty, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management compared with ropivacaine.

02

Conditions studied

  • Total Knee Arthroplasty
03

In context

Lead sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd. is the lead sponsor of 61 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Scheduled to undergo primary unilateral total knee arthroplasty under general anesthesia.
  3. Male or female,aged 18-75 years inclusive
  4. (BMI) 18-28 kg/m2 inclusive
  5. (ASA) Physical Status Classification Ⅰ\~Ⅱ

Exclusion criteria

Exclusion Criteria:

  1. Subjects with deformity of the involving operative limb, or other neuropathy
  2. Subjects with a history of new myocardial infarction or unstable angina within 6 months prior to randomization;
  3. Subjects with a history of ischemic stroke or (TIA)
  4. Subjects with a history of mental system diseases and cognitive dysfunction
  5. Combination of other pain conditions that may affect postoperative pain assessment
  6. Persistent or recurrent nausea and/or vomiting due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer
  7. Subjects with a history of deep vein thrombosis-related disease
  8. abnormal clinical laboratory test value
  9. Allergic to a drug ingredient or component
  10. Use of any of medications, which affect drug metabolism or analgesia evaluation, within 5 half-lives or as specified prior to the study surgical procedure
  11. History of alcohol abuse or prescription and/or illicit drug abuse
  12. Subjects with special diets (including tobacco, grapefruit and caffeine)
  13. Pregnant or nursing women
  14. No during the specified period of time
  15. Participated in clinical trials of other drugs (received experimental drugs)
  16. The inestigators determined that other conditions were inappropriate for participation in this clinical trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    dose 1

    Experimental: HR18034 190mg (10ml) Intervention: Drug: HR18034 Active Comparator: Ropivacaine Hydrochloride Injection Ropivacaine Hydrochloride Injection 50mg (10mL) Intervention: Drug: Ropivacaine Hydrochloride Injection

    Drug: HR18034;Ropivacaine Hydrochloride Injection

  • Experimental
    dose 2

    Experimental: HR18034 285mg (15ml) Intervention: Drug: HR18034 Active Comparator: Ropivacaine Hydrochloride Injection Ropivacaine Hydrochloride Injection 75mg (15mL) Intervention: Drug: Ropivacaine Hydrochloride Injection

    Drug: HR18034;Ropivacaine Hydrochloride Injection

  • Experimental
    dose 3

    Experimental:HR18034 380mg (20ml) Intervention: Drug: HR18034 Active Comparator: Ropivacaine Hydrochloride Injection Ropivacaine Hydrochloride Injection 100mg (20mL) Intervention: Drug: Ropivacaine Hydrochloride Injection

    Drug: HR18034;Ropivacaine Hydrochloride Injection

Interventions

  • DrugHR18034;Ropivacaine Hydrochloride Injection

    Drug pages: HR18034 · Ropivacaine

    Drug: HR18034 Drug: Ropivacaine Hydrochloride Injection Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management. Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution

06

What researchers measure

Primary outcomes

  1. AUC0-72 of the NRS-R pain intensity scores.

    AUC of NRS pain intensity scores at rest (NRS-R) through 72 hours after the beginning of study drug administration.

    Time frame: 0 to 72 hours

Secondary outcomes

  1. AUC of the NRS-R pain intensity scores.

    AUC of NRS pain intensity scores at rest (NRS-R) for time periods 0-24, 0-48 hours.

    Time frame: 0-24, 0-48 hours

  2. AUC of the NRS-A pain intensity scores.

    AUC of NRS pain intensity scores at activity (NRS-A) for time periods 0-24, 0-48, 0-72 hours.

    Time frame: 0-24, 0-48, 0-72 hours

  3. Pain intensity assessed using an 11-point NRS ranging.

    11-point Numercal Rating Scale ranging from a score of 0 to 10. Pain-free defined as an NRS of 0 or 1. Worst imaginable pain defined as an NRS of 10

    Time frame: Baseline till 72 hours after the beginning of study drug administration

  4. Proportion of subjects who used no rescue opioid analgesic.

    Proportion of subjects who used no rescue opioid analgesic through 0-24, 24-48, 48-72 and 0-72 hours after the beginning of study drug administration.

    Time frame: 0-24, 24-48, 48-72, 0-72 hours

  5. Total rescue analgesic consumption.

    Total rescue analgesic consumption through 0-24, 24-48, 48-72 and 0-72 hours after the beginning of study drug administration.

    Time frame: 0-24, 24-48, 48-72, 0-72 hours

  6. Time to the first postoperative use of rescue opioid analgesics.

    Time to the first postoperative use of rescue opioid analgesics 0-72 hours after the beginning of study drug administration.

    Time frame: 0-72hours

  7. Quadriceps muscle strength score.

    Quadriceps muscle strength score at 6, 8, 12, 16, 20, 24, 36, 48 and 72 hours.

    Time frame: Baseline till 72 hours after the beginning of study drug administration

  8. Subjects' satisfaction rating

    Subjects' satisfaction rating with postsurgical pain control at 72 hours.

    Time frame: 72 hours

  9. Investigators' satisfaction rating

    Investigators' satisfaction rating with postsurgical pain control at 72 hours.

    Time frame: 72 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Dec 2024, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Sep 30, 2022
StartActual
Oct 20, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05561309
Responsible party
Sponsor
First posted
Sep 30, 2022
Start date
Oct 20, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 4, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HR18034 · Ropivacaine

Start the discussion